# Mixed Connective Tissue Disease and Overlap Syndromes

## Introduction

Mixed connective tissue disease is characterized by the presence of high-titer anti-U1 RNP antibodies in combination with overlapping clinical features of systemic lupus erythematosus, systemic sclerosis, and polymyositis/dermatomyositis. First described by Sharp and colleagues in 1972 as a distinct entity with a favorable prognosis, MCTD remains the subject of ongoing debate regarding whether it represents a truly distinct disease or an overlap or transitional state that may eventually evolve into a defined connective tissue disease. Overlap syndromes involve the coexistence of clinical features meeting classification criteria for two or more defined connective tissue diseases. Undifferentiated connective tissue disease is the most common early presentation encountered in rheumatology practice, representing patients with autoimmune features that do not yet satisfy criteria for any specific CTD.

## Mixed Connective Tissue Disease

### Diagnostic Features

There are no universally accepted classification criteria for MCTD, with the Alarcon-Segovia and Kasukawa criteria being the most commonly used. The Alarcon-Segovia criteria, with a sensitivity of 63 percent and specificity of 86 percent, require a serologic criterion of anti-U1 RNP at a titer of 1:1600 or greater, combined with at least 3 of 5 clinical features: edema of the hands or swollen fingers, synovitis, myositis, Raynaud phenomenon, and acrosclerosis. The Kasukawa criteria require anti-U1 RNP positivity plus Raynaud phenomenon or swollen hands, plus features from at least 2 of 3 disease categories: SLE-like, SSc-like, and PM-like features.

### Clinical Manifestations

Raynaud phenomenon occurs in more than 90 percent of patients with MCTD and is frequently the presenting symptom. Puffy or swollen hands with sausage-like swelling of the fingers represent an early hallmark of the disease. Polyarthritis is typically non-erosive and similar in pattern to SLE. Myositis presents as proximal weakness with elevated creatine kinase and may respond to glucocorticoid therapy. Esophageal dysmotility with reduced lower esophageal sphincter pressure and reflux mirrors the gastrointestinal involvement seen in systemic sclerosis. Pulmonary hypertension is the most feared complication and the leading cause of MCTD-related death, with prevalence estimates ranging from 10 to 45 percent. Interstitial lung disease in an NSIP pattern occurs but is less common than in systemic sclerosis. Serositis, including pleuritis and pericarditis, is a recognized feature. Trigeminal neuropathy, though uncommon, is relatively specific for MCTD. Importantly, severe nephritis is rare in MCTD compared to SLE, and central nervous system disease is uncommon.

### Serology

Anti-U1 RNP is the defining antibody, present at high titers of 1:1600 or equivalent, directed against the U1 small nuclear ribonucleoprotein. ANA is positive at high titer with a speckled pattern. Rheumatoid factor is positive in approximately 50 percent of patients. Anti-dsDNA antibodies are usually absent, and their development should prompt consideration that the disease may be evolving toward SLE. Anti-CCP is occasionally positive. Complement levels are usually normal, unlike the hypocomplementemia typically seen in active SLE.

### Natural History and Prognosis

Some patients with MCTD evolve into a more defined connective tissue disease, including SLE, SSc, or polymyositis, over time. Approximately 30 percent develop additional autoantibodies and may be reclassified during follow-up. The overall prognosis is generally better than that of SLE or systemic sclerosis, but the development of pulmonary arterial hypertension significantly worsens outcomes. Ten-year survival is approximately 80 to 90 percent, comparable to SLE.

<image>A Venn diagram illustration showing the overlap features of MCTD. Three overlapping circles represent SLE (blue), SSc (green), and PM/DM (red). In the SLE circle: arthritis, serositis, cytopenias, anti-dsDNA. In the SSc circle: sclerodactyly, esophageal dysmotility, ILD, PAH. In the PM/DM circle: proximal myopathy, elevated CK, Gottron papules. In the central overlap area (MCTD): anti-U1 RNP, Raynaud phenomenon, swollen hands, all three disease features. In bilateral overlaps, show features shared between two diseases. Outside the diagram, show a box for UCTD (undifferentiated CTD) with features that do not meet any complete criteria. Label clearly and use distinct colors for each domain.</image>

## Management of MCTD

Management of MCTD is directed at the predominant disease manifestations. Raynaud phenomenon is treated with calcium channel blockers such as nifedipine and amlodipine, phosphodiesterase-5 inhibitors, and topical nitroglycerin. Arthritis responds to hydroxychloroquine, methotrexate, and low-dose glucocorticoids. Myositis requires glucocorticoids combined with a steroid-sparing agent such as methotrexate, azathioprine, or mycophenolate mofetil. Interstitial lung disease is managed with mycophenolate, azathioprine, or cyclophosphamide for progressive disease. Pulmonary arterial hypertension is treated according to established PAH guidelines with endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin pathway agents, and annual screening with echocardiography and pulmonary function tests is recommended. Serositis responds to NSAIDs, glucocorticoids, and colchicine. Hydroxychloroquine is recommended for all MCTD patients based on a rationale similar to its use in SLE. High-dose glucocorticoids should be avoided when possible due to the risk of SSc-like complications.

| Feature | MCTD | SLE | SSc (diffuse) | PM/DM |
|---------|------|-----|---------------|-------|
| Defining antibody | **Anti-U1 RNP** (high titer ≥1:1600) | Anti-dsDNA, anti-Sm | Anti-Scl-70, anti-RNA pol III | MSAs (Jo-1, MDA5, etc.) |
| Raynaud phenomenon | >90% | 20–40% | >95% | 10–20% |
| Arthritis | Non-erosive (SLE-like) | Non-erosive | Arthralgias; friction rubs | Mild arthralgias |
| Myositis | Common | Mild | Mild (overlap possible) | **Defining feature** |
| ILD | Less common than SSc | Uncommon | 40–75% | Common (antisynthetase) |
| PAH | **Leading cause of death** (10–45%) | Uncommon | 8–12% (limited > diffuse) | Rare |
| Severe nephritis | **Rare** | 40–60% | 5–10% (renal crisis) | Rare |
| Complement levels | Usually normal | Low (active disease) | Normal | Normal |
| 10-year survival | ~80–90% | ~90% | ~65–75% | Variable by subtype |

## Overlap Syndromes

### Rhupus (RA-SLE Overlap)

Rhupus describes the coexistence of erosive inflammatory arthritis consistent with rheumatoid arthritis and SLE features, occurring in approximately 1 to 2 percent of SLE patients. The distinguishing feature is the presence of radiographic erosions, which are not typical of lupus arthropathy. Antibody profiles demonstrate dual positivity with RF, anti-CCP, ANA, and anti-dsDNA. Management requires treatment of both disease processes, incorporating methotrexate, hydroxychloroquine, and biologics, with careful attention to lupus nephritis when selecting therapeutic agents.

### Scleroderma-Myositis Overlap

The scleroderma-myositis overlap is defined by anti-PM-Scl antibodies, including anti-PM-Scl75 and anti-PM-Scl100, and presents with myositis, sclerodactyly, ILD, mechanic's hands, and Raynaud phenomenon. The SSc component tends to be milder with less severe skin fibrosis. Anti-Ku antibodies are also associated with this overlap phenotype. Treatment involves glucocorticoids with steroid-sparing agents such as methotrexate or mycophenolate mofetil.

### SLE-SSc Overlap

SLE-SSc overlap presents with concurrent features of both diseases and often involves anti-U1 RNP positivity. Patients may develop lupus nephritis alongside scleroderma skin changes, requiring monitoring for both PAH and ILD.

### SS-RA Overlap (Secondary Sjogren)

Secondary Sjogren syndrome occurs in 10 to 30 percent of RA patients, identified by anti-Ro/SSA positivity and sicca symptoms. These patients carry an increased lymphoma risk compared to RA alone, and both diseases should be managed independently.

## Undifferentiated Connective Tissue Disease (UCTD)

### Definition and Features

Undifferentiated connective tissue disease represents patients with autoimmune features, including ANA positivity and suggestive symptoms, that do not meet classification criteria for any defined connective tissue disease. The common presentation is a young woman with Raynaud phenomenon, arthralgias, positive ANA, and possibly anti-Ro or anti-RNP antibodies. Up to 25 percent of patients referred to rheumatology for possible CTD fall into this category. Proposed criteria from Mosca in 2014 define UCTD as signs and symptoms suggestive of CTD plus ANA positivity plus disease duration of at least 3 years without meeting criteria for a defined CTD.

### Natural History

Approximately 30 percent of UCTD patients evolve to a defined CTD within 5 years, most commonly SLE. Another 30 percent remain UCTD indefinitely, and 30 to 40 percent experience remission or have minimal symptoms. Risk factors for evolution to SLE include anti-dsDNA antibodies, low complement levels, cytopenias, younger age, and the presence of multiple autoantibodies.

### Management

Management of UCTD is conservative, employing NSAIDs and hydroxychloroquine for arthralgias and Raynaud management. Hydroxychloroquine may prevent evolution to SLE, as preliminary data from the PLUS trial suggest that it reduces progression from incomplete lupus erythematosus to SLE. Clinical and serologic follow-up every 6 to 12 months is recommended, with particular vigilance for new organ involvement. Patient education should include reassurance that UCTD is often mild, along with discussion of the possibility of disease evolution over time.

<image>A timeline diagram showing the natural history and evolution of undifferentiated connective tissue disease (UCTD). Start on the left with "Initial presentation: ANA+, nonspecific symptoms (arthralgias, Raynaud, fatigue)" and show three diverging pathways over a 5-10 year timeline: (1) Top pathway (~30%): Evolution to defined CTD, showing branching to SLE, MCTD, SSc, SS, or PM/DM with specific antibody development noted at transition points (e.g., anti-dsDNA → SLE, anti-Scl-70 → SSc). (2) Middle pathway (~30%): Stable UCTD remaining undefined. (3) Bottom pathway (~30-40%): Remission with resolution of symptoms. Include risk factors for evolution (young age, multiple antibodies, cytopenias, low complement) in an annotation box. Use arrows and color gradients to show progression over time.</image>

## Diagnostic Approach to Overlap Syndromes

The diagnostic approach to overlap syndromes requires a comprehensive autoantibody panel including ANA, anti-dsDNA, anti-Sm, anti-RNP, anti-Ro, anti-La, anti-CCP, RF, anti-Scl-70, anticentromere antibodies, myositis-specific antibody panels, and antiphospholipid antibodies. All clinical features should be documented systematically, with classification criteria for each possible CTD applied. Imaging should include CXR or HRCT for ILD, echocardiography for PAH, hand radiographs for erosions, and muscle MRI for myositis. Organ-specific evaluation is guided by clinical symptoms. Importantly, classification should be reassessed over time as the disease evolves and new manifestations emerge.

## Key Clinical Pearls

- High-titer anti-U1 RNP is the serologic hallmark of MCTD; low-titer anti-RNP can be seen in SLE
- PAH is the leading cause of death in MCTD; screen annually with echocardiography
- MCTD typically spares the kidneys (severe nephritis rare); if nephritis develops, reconsider SLE
- Trigeminal neuropathy, though uncommon, is relatively specific for MCTD
- UCTD patients with anti-dsDNA, low complement, and cytopenias are at highest risk for evolving to SLE
- "Overlap syndrome" is a clinical diagnosis; there are no formal classification criteria

## References
1. Sharp GC, et al. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148-159.
2. Alarcon-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Anti-nuclear Antibodies. 1987.
3. Mosca M, et al. Undifferentiated connective tissue diseases (UCTD): Simplified systemic autoimmune diseases. Autoimmun Rev. 2014;13(6):629-632.
4. Gunnarsson R, et al. Mixed connective tissue disease. Best Pract Res Clin Rheumatol. 2016;30(1):95-111.
5. Cappelli S, et al. To be or not to be, ten years after: Evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2012;41(4):589-598.